Emetogenic chemotherapy regimens and back pain were associated with higher symptom burden in older, vs younger, patients with ...

Data from the CEPHEUS trial support the use of D-VRd in patients with transplant-ineligible or -deferred multiple myeloma who can tolerate bortezomib. Adding daratumumab (Darzalex) to bortezomib ...

When treating patients with hormone-receptor positive, HER2-negative metastatic breast cancer, mutations necessitate the ...

Apalutamide decreased risk of death in mCSPC by 23% and 26% compared with enzalutamide and abiraterone acetate, respectively.

Panelists discuss how cardiovascular toxicity remains a significant concern with certain tyrosine kinase inhibitors (TKIs) used in chronic myeloid leukemia (CML) treatment, particularly with the older ...

Panelists discuss how eliminating the strict mealtime restrictions with the new nilotinib formulation addresses a significant unmet need in chronic myeloid leukemia (CML) treatment by reducing ...

The MindCap mobile app is likely feasible as an assessment for cognitive function of cancer survivors, although further data ...

The PRECURSOR intervention appeared feasible/acceptable, suggesting a need for patient-centered conversation in incurable ...

Real-World Data Shows Apalutamide Increases 24-Month OS in mCSPC ...

Kaifan Zhao, AGACNP-BC, PMHNP-BC, Wins ONN’s 2025 Extraordinary Healer® Award ...